The NSAID and CVD Balancing Act

An Expert Interview With Daniel Solomon, MD

Linda Brookes; Daniel Solomon, MD


August 30, 2011

In This Article

A Best Evidence Interview With Daniel Solomon, MD

About the Interviewee

Daniel Solomon, MD, MPH, is an Associate Professor of Medicine at Harvard Medical School and Chief of the Section of Clinical Sciences in Rheumatology at Brigham and Women's Hospital, where he is coappointed in the Division of Pharmacoepidemiology and Pharmacoeconomics. The focus of his research is health services research, quality of care, and pharmacoepidemiology as it pertains to rheumatic diseases and osteoporosis. Specific topics of interest include: indicators of quality prescribing, patterns of medication use for osteoporosis, quality improvement in osteoporosis care, and cardiovascular disease in patients with rheumatoid arthritis. Dr. Solomon is the Past Chair of the Quality of Care Committee of the American College of Rheumatology. He serves as an unpaid member of the Executive Committee on the PRECISION trial assessing the cardiovascular safety of celecoxib vs nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) and as an unpaid member of the Data and Safety Monitoring Board for trials testing a nerve growth factor inhibitor, tanezumab.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.